Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RYTM Rhythm Pharmaceuticals Inc.

已收盘 10-29 16:00:00 EDT

93.07

+1.10

+1.20%

盘后93.07

+0.000.00%

19:30 EDT

最高94.16	最低92.52	成交量76.05万
今开93.00	昨收91.97	日振幅1.79%
总市值64.08亿	流通市值60.86亿	总股本6,885万
成交额7,089万	换手率1.16%	流通股本6,539万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":93.07,"timestamp":1793304000000,"preClose":91.97,"halted":0,"volume":760468,"hourTrading":{"tag":"盘后","latestPrice":93.07,"preClose":93.07,"latestTime":"19:30 EDT","volume":126243,"amount":11749239.36,"timestamp":1793316602271,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.011960421876698862,"floatShares":65394076,"shares":68852082,"eps":-3.117162,"marketStatus":"已收盘","change":1.1,"latestTime":"10-29 16:00:00 EDT","open":93,"high":94.16,"low":92.515,"amount":70888739.47534,"amplitude":0.017886,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.117162,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793347200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":91.97,"preHourTrading":{"tag":"盘前","latestPrice":91.98,"preClose":91.97,"latestTime":"09:15 EDT","volume":2,"amount":188.48001,"timestamp":1793279701036,"change":0.01,"changeRate":0.000109,"amplitude":0.049146},"postHourTrading":{"tag":"盘后","latestPrice":93.07,"preClose":93.07,"latestTime":"19:30 EDT","volume":126243,"amount":11749239.36,"timestamp":1793316602271,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.670067,"impliedVol":0.3982,"impliedVolPercentile":0.0996},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"1150781232","title":"财报前瞻 | Rhythm Pharmaceuticals Inc.本季度营收预计增66.15%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1150781232","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150781232?lang=zh_cn&edition=full","pubTime":"2026-10-27 10:05","pubTimestamp":1793066752,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.将于2026年11月03日发布最新季度财报，市场聚焦营收高增的持续性与亏损收窄节奏。市场一致预期本季度公司营收为8,424.73万美元，同比增66.15%；调整后每股收益为-0.71，同比改善1.85%；未见公开一致预期的毛利率及净利润或净利率预测，公司亦未披露明确指引。公司收入结构以产品销售为主，上季度产品收入为7,125.50万美元，同比增长46.91%，高毛利特性增强收入质量与可持续性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Rhythm Pharmaceuticals Inc.本季度营收预计增66.15%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186986692","title":"Rhythm制药宣布加拿大卫生部批准Imcivree®（Setmelanotide）用于4岁及以上获得性下丘脑肥胖成人和儿童患者的体重管理","url":"https://stock-news.laohu8.com/highlight/detail?id=1186986692","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186986692?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:05","pubTimestamp":1790078747,"startTime":"0","endTime":"0","summary":"Rhythm制药公司今日宣布，加拿大卫生部已正式批准其药物Imcivree上市，用于治疗获得性下丘脑肥胖。该适应症覆盖了成年患者以及年满4周岁的儿科患者群体，旨在帮助这些人群实现体重管理。此次加拿大卫生部的授权，基于临床研究数据的坚实支撑，证实了Imcivree在这一特定患者群体中能够带来具有临床意义的体重减轻。此次在加拿大的获批，是Rhythm制药公司在扩展其罕见肥胖症治疗版图道路上迈出的又一步坚实步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RYTM","BK4588","MEDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181502048","title":"德意志银行首次覆盖Rhythm Pharmaceuticals，给予持有评级，目标价120美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181502048","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181502048?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:10","pubTimestamp":1787915412,"startTime":"0","endTime":"0","summary":"德意志银行宣布，首次对Rhythm Pharmaceuticals展开覆盖研究。该行给予这家制药公司\"持有\"评级，并将目标股价设定在每股120美元。这一动作，为市场参与者提供了新的分析视角。在生物制药领域，投资机构的态度往往具有风向标意义。Rhythm Pharmaceuticals未来的股价走势，是否会朝着120美元的目标价位靠拢，值得投资者持续关注。德意志银行此次给出的评级，既不悲观亦非强烈看多，反映出一种中性的市场预期。这一决策背后，或许暗含着对该公司现有产品线及在研管线的综合评估。市场对此举的反应，尚待观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MEDI","BK4139","RYTM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184462177","title":"Rhythm Pharmaceuticals宣布Imcivree®（Setmelanotide）在英国获批扩大适应症，用于治疗下丘脑损伤或受损导致的获得性下丘脑肥胖患者的肥胖及饥饿控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1184462177","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184462177?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:05","pubTimestamp":1786449915,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals（股票代码：RYTM）今日宣布，其核心药物Imcivree®（Setmelanotide）已获得英国药品监管机构的授权，针对特定患者群体——即因下丘脑损伤或功能受损而罹患获得性下丘脑肥胖的患者——的治疗适应症实现显著扩展。标志着该药物在肥胖及饥饿控制领域的应用迈入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MEDI","BK4588","RYTM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185808167","title":"Rhythm Pharmaceuticals：将与英国国家医疗服务体系紧密合作，敲定Imcivree覆盖指南以应对获得性肥胖症","url":"https://stock-news.laohu8.com/highlight/detail?id=1185808167","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185808167?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:02","pubTimestamp":1786449769,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.宣布，将与英国国家医疗服务体系（NHS）密切协作，共同敲定针对其药物Imcivree的覆盖指南。这一举措旨在为获得性肥胖症患者提供治疗保障。双方的合作将聚焦于如何精准界定覆盖范围，确保患者能够及时获得这一创新疗法。通过细化指南，他们期望能加速药物纳入医保的进程，从而缓解肥胖症带来的公共健康压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","BK4588","BK4585","BK4139","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154959787","title":"Rhythm Pharmaceuticals预估2026年非GAAP运营支出为3.63亿至3.97亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154959787","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154959787?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:17","pubTimestamp":1785842229,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals公司近日发布了财务预估。对于截至2026年12月31日的财年，该公司预计其非GAAP运营支出将在3.63亿美元至3.97亿美元之间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","RYTM","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161176907","title":"异动解读 | 盘前大涨5.58%：Rhythm Pharmaceuticals公布Rm-718二期试验积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1161176907","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161176907?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:11","pubTimestamp":1785841874,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM) 今日盘前股价大涨5.58%，引发市场关注。消息面上，公司公布了在研药物Rm-718的二期临床试验初步数据，该药物在治疗获得性下丘脑肥胖方面展现出积极的疗效信号，且耐受性良好，常见不良反应为注射部位反应、恶心及呕吐，均属可控范围。这一积极进展为相关治疗领域带来了突破希望，提振了投资者对公司前景的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126936039","title":"Rhythm Pharmaceuticals公布二期试验初步数据：Rm-718在获得性下丘脑肥胖中展现积极疗效信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1126936039","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126936039?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:56","pubTimestamp":1785840989,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.（简称：Rhythm Pharmaceuticals）近日公布了其二期临床试验的初步数据。该试验结果显示，实验性药物Rm-718在治疗获得性下丘脑肥胖方面，成功呈现出了积极的疗效信号。这一发现为相关领域的治疗探索带来了令人鼓舞的进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4585","BK4588","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157936013","title":"Rhythm Pharmaceuticals在研药物Rm-718耐受性良好，常见不良反应为注射部位反应、恶心及呕吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1157936013","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157936013?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:56","pubTimestamp":1785840974,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals所研发的候选药物Rm-718，目前展现出令人鼓舞的耐受性特征。在临床应用中，最常被观察到的不良事件集中在注射部位反应、恶心以及呕吐等方面。这些副作用均属于可控范围，且患者整体对该药物的承受能力表现良好，为后续的临床推进提供了积极的支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","RYTM","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156882005","title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增54.19%，机构多头占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1156882005","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156882005?lang=zh_cn&edition=full","pubTime":"2026-07-29 00:40","pubTimestamp":1785256854,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.将于2026年08月04日发布最新季度财报，市场关注核心产品动能与亏损收窄路径。市场一致预期本季度Rhythm Pharmaceuticals Inc.营收为6,727.69万美元，同比增54.19%；调整后每股收益预计为-0.82美元，同比变动-21.65%。覆盖Rhythm Pharmaceuticals Inc.的机构中，看多观点占主导地位，机构一致认为公司核心产品的销售动能与适应症拓展形成双轮驱动，支撑本季度营收同比增54.19%的市场预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增54.19%，机构多头占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170739948","title":"Rhythm Pharmaceuticals宣布《新英格兰医学杂志》发表针对获得性下丘脑肥胖症的3期Transcend试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170739948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170739948?lang=zh_cn&edition=full","pubTime":"2026-07-09 05:09","pubTimestamp":1783544956,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 宣布，其针对获得性下丘脑肥胖症的3期Transcend临床试验结果，已获国际顶尖医学期刊《新英格兰医学杂志》发表。研究聚焦于评估公司在研疗法对因下丘脑损伤导致严重肥胖患者群体的疗效与安全性。获得性下丘脑肥胖是一种罕见且严重的疾病，常由脑部肿瘤、手术或创伤对下丘脑造成损伤引发。此次在顶级期刊上公布详细数据，为后续与监管机构的沟通及潜在疗法的推进奠定了坚实的科学基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MEDI","BK4585","BK4139","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131755559","title":"Rhythm Pharmaceuticals公布多项新数据：展示MC4R激动剂在获得性下丘脑肥胖、Bardet-Biedl综合征及Prader-Willi综合征中的研究成果于ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1131755559","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131755559?lang=zh_cn&edition=full","pubTime":"2026-06-16 04:02","pubTimestamp":1781553736,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 宣布，将在ENDO 2026大会上展示其MC4R激动剂针对获得性下丘脑肥胖、Bardet-Biedl综合征以及Prader-Willi综合征的多项最新研究数据。这些报告将揭示该疗法在多种罕见遗传性肥胖疾病中的最新进展与潜在疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183006967","title":"Rhythm Pharmaceuticals六个月数据显示Setmelanotide显著改善普瑞德-威利综合征多项指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1183006967","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183006967?lang=zh_cn&edition=full","pubTime":"2026-06-13 20:03","pubTimestamp":1781352198,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 于2026年5月7日公布的最新六个月临床数据显示，其核心药物Setmelanotide在治疗普瑞德-威利综合征方面展现出积极疗效，显著改善了多项关键临床终点。\n该数据进一步证实了Setmelanotide在控制与PWS相关的严重饥饿感和体重管理方面的潜力。研究结果显示，接受治疗的患者在多个评估维度上均获得了具有统计学意义和临床意义的改善。\n这些积极结果加强了该药物作为PWS患者潜在重要治疗选择的地位，为后续的监管申请和临床开发路径提供了关键支持。公司将持续推进相关研究，以期为这一罕见病患者群体带来新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RYTM","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114862762","title":"Rhythm Pharmaceuticals 将公布评估 Setmelanotide 在普瑞德-威利综合征患者中的六个月中期二期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1114862762","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114862762?lang=zh_cn&edition=full","pubTime":"2026-06-13 04:02","pubTimestamp":1781294534,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 即将公布其药物 Setmelanotide 用于治疗普瑞德-威利综合征患者的二期临床试验中期结果。此次公布的数据将涵盖为期六个月的研究阶段。\n该消息备受市场关注，因 Setmelanotide 的疗效数据可能对公司的未来前景产生重要影响。投资者正密切关注试验结果，以评估该疗法在应对这一罕见遗传性疾病方面的潜力与进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143456364","title":"异动解读 | 第一季度营收增长超预期，Rhythm Pharmaceuticals盘中大涨12.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143456364","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143456364?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:52","pubTimestamp":1777989161,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) 今日盘中股价大幅上涨12.79%，表现强劲。消息面上，公司公布了第一季度财务业绩，显示产品收入达到6010万美元，较去年同期的3270万美元实现显著增长。营收增长主要得益于其针对获得性下丘脑肥胖症的药物IMCIVREE的上市销售。此外，公司第一季度净亏损为5560万美元，基本符合分析师预期。市场对该业绩反应积极。根据LSEG数据，在覆盖该股的16家券商中，有15家给予“买入”或更高评级，目标价中位数为140美元，显示出分析师对公司未来前景的看好。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177130155","title":"Rhythm Pharmaceuticals宣布Imcivree®（司美兰肽）获欧盟委员会授予上市许可，用于治疗获得性下丘脑性肥胖患者的肥胖及饥饿控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1177130155","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177130155?lang=zh_cn&edition=full","pubTime":"2026-05-01 18:56","pubTimestamp":1777632976,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM) 近日宣布，其创新药物Imcivree®（活性成分：司美兰肽）已正式获得欧盟委员会颁发的上市许可。该批准标志着该药物可用于治疗获得性下丘脑性肥胖症患者的肥胖问题及饥饿控制。\n此次授权为患有该罕见疾病的患者提供了新的治疗选择，有望改善其生活质量。公司表示将继续推进相关临床工作，确保药物可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518276046","title":"Rhythm Pharmaceuticals, Inc.盘中异动 早盘快速下挫5.01%报48.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518276046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518276046?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:30","pubTimestamp":1741617055,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时30分，Rhythm Pharmaceuticals, Inc.股票出现异动，股价大幅下挫5.01%。Rhythm Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3457.49%、730.68%、517.45%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Rhythm Pharmaceuticals, Inc.公司简介：Rhythm Pharmaceuticals Inc 是一家生物制药公司，从事罕见病治疗方法的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223055964044b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223055964044b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","RYTM","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517456009","title":"大摩：假定Rhythm Pharmaceuticals(RYTM.US)增持评级, 目标价由72.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517456009","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517456009?lang=zh_cn&edition=full","pubTime":"2025-03-08 01:53","pubTimestamp":1741369983,"startTime":"0","endTime":"0","summary":"大摩：假定Rhythm Pharmaceuticals(RYTM.US)增持评级, 目标价由72.00美元调整至72.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08015348605007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517404949","title":"Stifel：重申Rhythm Pharmaceuticals(RYTM.US)买入评级, 目标价78.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517404949","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517404949?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:01","pubTimestamp":1741197678,"startTime":"0","endTime":"0","summary":"Stifel：重申Rhythm Pharmaceuticals(RYTM.US)买入评级, 目标价78.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06020148550854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516480445","title":"Rhythm Pharmaceuticals, Inc.2024财年实现净利润-2.61亿美元，同比减少41.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516480445","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516480445?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931238,"startTime":"0","endTime":"0","summary":"3月3日，Rhythm Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-2.61亿美元，同比减少41.08%；其中营业收入为1.30亿美元，同比增加67.89%，每股基本收益为-4.34美元。机构评级：截至2025年3月3日，当前有11家机构对Rhythm Pharmaceuticals, Inc.目标价做出预测，其中目标均价为74.73美元，其中最低目标价为60.00美元，最高目标价为94.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000058abe4aca5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000058abe4aca5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":0.0378},{"period":"1month","weight":-0.0669},{"period":"3month","weight":-0.1302},{"period":"6month","weight":0.1242},{"period":"1year","weight":-0.1894},{"period":"ytd","weight":-0.1408}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rhythm Pharmaceuticals, Inc.是一家特拉华州的公司，成立于2013年2月。该公司是一家全球性、商业阶段的生物制药公司，致力于改变患有罕见神经内分泌疾病的患者及其家人的生活。该公司专注于推进黑皮质素-4受体激动剂，包括他们的主要资产IMCIVREE，作为一种精准药物，旨在治疗由罕见的MC4R通路疾病引起的食欲亢进和严重肥胖。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051908},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.048958},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.056668},{"month":4,"riseRate":0.555556,"avgChangeRate":0.013671},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045608},{"month":6,"riseRate":0.555556,"avgChangeRate":0.069919},{"month":7,"riseRate":0.444444,"avgChangeRate":0.238637},{"month":8,"riseRate":0.777778,"avgChangeRate":0.220515},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.047508},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.017244},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}